

Capital Small Finance Bank

19 June 2024

Well capitalised to accelerate growth

MANAGEMENT MEET UPDATE

| | |
|---------------|-------------------|
| Sector: Banks | Rating: NOT RATED |
| CMP: Rs 350 | Target Price: NA |

Stock Info

| | |
|----------------|-----------------------|
| Sensex/Nifty | 77,337 /23,521 |
| Bloomberg | CAPITALS IN |
| Equity shares | 45mn |
| 52-wk High/Low | Rs 469 / 313 |
| Face value | Rs 10 |
| M-Cap | Rs 15.7bn/ USD 0.19bn |
| 3-m Avg value | USD 0.5mn |

Financial Snapshot (Rs mn)

| Y/E March | FY22 | FY23 | FY24 |
|-------------|-------|-------|-------|
| NII | 2,553 | 3,220 | 3,452 |
| PPP | 1,132 | 1,487 | 1,549 |
| PAT | 626 | 936 | 1,115 |
| PAT Gr. (%) | 53% | 50% | 19% |
| EPS (Rs) | 18.4 | 27.4 | 30.4 |
| EPS Gr. (%) | 53% | 49% | 11% |
| BV/Sh (Rs) | 152 | 178 | 266 |

Ratios

| | | | |
|---------------|------|------|------|
| NIM (%) | 3.7 | 4.2 | 3.9 |
| C/I ratio (%) | 63.4 | 60.0 | 62.5 |
| RoA (%) | 0.9 | 1.2 | 1.3 |
| RoE (%) | 12.9 | 16.6 | 14.6 |


Valuations

| | | | |
|----------|----|----|------|
| P/E (x) | NA | NA | 11.5 |
| P/BV (x) | NA | NA | 1.3 |

Shareholding pattern (%)

| | Mar'24 |
|----------|--------|
| Promoter | 18.9 |
| -Pledged | |
| FII | 1.4 |
| DII | 33.1 |
| Others | 46.7 |

Stock Performance



Manjith Nair

manjithnair@systematixgroup.in
+91 22 6704 8065

Pashmi Chheda

pashmichheda@systematixgroup.in
+91 22 6704 8063

Nirali Chheda

niralichheda@systematixgroup.in
+91 22 6704 8019

We recently interacted with the management of Capital Small Finance Bank (Capital SFB) represented by MD and CEO - Mr Sarvjit Singh Samra and CFO - Mr Munish Jain. Key takeaways from the meeting were: (1) Flush from the capital infusion of Rs 5.23bn, post the IPO in Feb'24, the bank is geared towards delivering a loan growth of 22-24% in FY25. FY24 loan growth at 12% was subdued mainly due to the excess leverage on the balance sheet. (2) Management guided for C-D ratio to increase to mid-80's in the medium-term vs 79% average C-D ratio for FY24. (3) With deposit costs broadly stabilized, going forward, margins are expected to increase due to incrementally higher C-D ratio and flow through of MCLR rate hikes taken in 4Q/FY24. (4) The bank currently has presence in the four northern states of Punjab, Haryana, Rajasthan and Himachal Pradesh along with the territories of Chandigarh and NCR. It plans to start business in a new state during this financial year. Haryana is expected to be the next growth driver with product profile and recovery trends like those in its core state of Punjab. Penetration in its core market of Punjab is 1.74% (in 2023), implying headroom for accelerating growth. (5) In FY25, the bank plans to increase the extant branch network of 177 branches by ~ 25 additional branches. Opex to asset ratio is likely to remain around current levels of 2.95% as opex increase from new branch additions will be offset by greater operating leverage stemming from maturity of existing branches. (6) In 4QFY24, GNPA/NNPA, at 2.8%/1.4%, remained broadly stable yoy and improved - 21bps / -13bps qoq. NNPA is expected to come below 1% by Sep'25. Historically, while slippage ratio has been ~1.75-2.75%, the bank has maintained low GNPA ratios driven by focus on recoveries and more than adequate collateral cover. (7) The bank delivered FY24 RoA of 1.3% and guided for FY25 RoA to increase to 1.4% on the back of NIM expansion (stemming from on higher leverage) and sweating of existing branch infrastructure. The stock currently trades at trailing P/B of 1.27x for FY24 RoA of 1.3% and RoE of 14.6%.

Loan growth outlook of 22-24% on low base, remains conservative: The bank's key segments include Agri (37% of loans), Mortgages (26%), MSME & trading loans (19%) and Other loans (17%). While the share of MSME advances has declined to 19% in FY24 vs 26% in FY21, due to COVID impact, going forward, the management expects growth to pick-up on the back of 'Make in India' initiatives coupled with the election related uncertainties being behind. The share of corporate book, consisting of loans to NBFCs, increased to 9% in FY24 vs 8% in FY23, and is expected to remain around these levels. In FY24, share of advances from outside Punjab has increased to 17.4% vs 14.81% in FY23. While FY24 loan growth of 12% yoy was subdued due to constraints from higher leverage, it should normalize to 20%+ levels from FY25. That said, the FY25 guidance of 22-24% (despite a low base) is also soft as compared to key peer SFBs despite a relatively smaller book size of Rs 61bn mainly due to its conservative approach while expanding to newer geographies with the new branch additions likely to be back ended in 2HFY25.

High retail deposit base, a key strength: The bank's strength is its liability customer base of 0.65 Mn customers which is ~10x its asset customer base. 93% of its liabilities are retail in nature with CASA ratio of 38.3%, highest amongst the listed SFBs. The CASA is also relatively price-inelastic with average SA rate of 3.5% as compared to other mid-sized SFBs offering 7%+ SA rates. The bank continues to gain deposit market share in Punjab with incremental deposit market share of 1.63%, higher than

o/s deposit market share of 1.15%. The average deposit ticket size has also increased to Rs 42,000 vs 32,000 three years ago. **With average C-D ratio (79% as of Mar'24) remaining low vs peers, the bank has guided for the C-D ratio to increase to mid-80's in the medium term.**

Margins to be aided by C-D ratio improvement and flow through of MCLR rate hikes: The bank has been able to maintain through-cycle interest spreads between 5.5-5.9% as ~60% of its assets and liabilities are broadly floating, on either side of the balance sheet. While spreads/NIMs (5.6%/3.9%) declined by ~30bps in FY24 due to rising deposit costs, incremental retail TD rates have remained largely stable over the past few quarters (7.65% vs 7.55% a year ago) and with average maturity of the retail TD book being 1 year, **deposit costs have broadly stabilised. Going forward, margin expansion will be led by (i) improvement in C-D ratio which remains low at 79% vs other SFBs having 80-100%+. As per the management, 100bps increase in CDR leads to 5bps NIM expansion. (ii) flow through of MCLR rate hikes as 60-62% of the book is floating rate of which 80% of the book is MCLR linked and 35-40% of it will get repriced in 1Q.** MCLR increased by 35bps in FY24 out of which 25bps was in 4QFY24.

Opex to remain broadly stable on operating leverage: The bank guided for new branch additions of 25 in FY25 taking the total branch count to 200 vs 177 o/s as of Mar'24. However, despite the increased branch count it does not see material increase to opex as (i) opex increase from new branch additions will be offset by operating leverage from maturity of existing branches. (ii) While sourcing is done by branches, underwriting is done at regional, cluster and head-office levels which already have capacity to support 240-245 branches vs 177 o/s branches currently. **In FY25, opex to assets is likely to remain around current levels of 2.95%. Tech spends amount to 0.2% of assets and are unlikely to increase materially as (i) the bank has already purchased the license (and not a pay as you use model) of its core banking software (Intellect core arena) (ii) large part of its infrastructure is on private cloud, the capex for which is already done.**

Strong asset quality driven by focus on recoveries and adequate collateralisation: GNPA/NNPA at 2.8%/1.4% remained broadly stable yoy and improved -21bps / -13bps qoq. FY24 reported credit cost were 0.1% and historical average credit costs have been around ~0.2%, much lower vs other key lenders, mainly due to (i) secured nature of the loan book (ii) strong understanding of its core market (iii) close customer connect as 95% of sourcing is via branch channels and which are also responsible for upselling and recovery. The bank had almost Nil technical write-offs in FY24 and cumulative write-offs so far have been low at <Rs 6Mn, mainly attributable to strong recovery which is entirely in-house. While the bank has PDs (probability of default) between 1.75%-2.75%, it is partly offset by strong recovery rates of around 2%, leading to NNPA of ~1%. That said, SMA 1+2 increased to 4.3% in FY24 vs 3.5% in FY23 mainly due to lower growth and higher interest rates leading to higher EMIs impacting repayments. **PCR for next few years is likely to be around current 50% levels with 30% of the outstanding provisions as additional provisions, over and above the regulatory IRAC requirements. Further, the bank's initial estimates suggest a reduction in provision requirement on implementation of ECL norms. The bank expects Haryana to be the next growth driver and expects recovery trends to be like those in its core state of Punjab.**

The bank's risk underwriting strategy involves (i) nearly, 100% of the loans are secured with average ATS of Rs 1.4mn catering to a target segment of middle-income group customers, having annual income of Rs 0.4mn-4mn. (ii) In the **Agri segment (37% of loans)**, the bank targets customer segment with ticket size between Rs 0.5mn-2.5mn which ringfences it from political uncertainty. Primary security is in the form of the standing crop and secondary collateral is a legal mortgage of the Agri

land. The bank provides loan with LTV of 50% with the collateral valued at the ready reckoner rate which is lower than the market rate. The bank has not sold off any agri assets till date. (iii) in **mortgages**, the bank collateralizes a residential property only when the borrower possesses ownership title of the property for a minimum of 14 years and at LTV around ~70-75%. (iv) in **MSME**, in addition to a collateral, the bank also has security in the form of asset purchased with the loan like the machinery, stock/good purchased (v) in **NBFC lending**, the bank lends primarily to BBB+ and above rated non-MFI NBFCs. It also has a 5-10% FLDG arrangement for the lower rated NBFCs. (vi) **consumption loans** are given only to the bank's existing customers.


Key charts

Exhibit 1: Credit portfolio

| Agricultural Loans | | Mortgage Loans | | MSME & Trading Loans | | Other Loans | |
|----------------------|--------------------------|---|--|---|--|---|--|
| | 37% | | 26% | | 19% | | 17% |
| • Kisan Credit Card | • Agricultural Term Loan | • Housing Loan | • Loan Against Property | • Working Capital facility (CC / OD/WCTL) | • Project Financing | • Machinery Loans | • Term loans to NBFCs |
| • Term Loans to MFIs | | | | | | | • Gold Loans |
| | Gross Advances | Rs. 2,293 crores as of March 2024 | Rs. 2,137 crore as of March 2023 | Rs. 1,624 crores as of March 2024 | Rs. 1,434 crore as of March 2023 | Rs. 1,182 crores as of March 2024 | Rs. 1,120 crore as of March 2023 |
| | ATS | Rs 12.4 lakhs | | Rs 11.7 lakhs | | Rs 18.6 lakhs | Rs 1,719 lakhs |
| | NNPA | 1.69 % as of March 2024 | 1.40 % as of March 2023 | 0.86 % as of March 2024 | 0.63 % as of March 2023 | 2.73 % as of March 2024 | NIL as of March 2024 |
| | Interest Yield | 12.08% as of March 2024 | 12.02% as of March 2023 | 11.81% as of March 2024 | 11.72% as of March 2023 | 10.74% as of March 2024 | 11.15% as of March 2024 |
| | | | | | | | 9.72% as of March 2024 |
| | | | | | | | 9.39% as of March 2023 |


Source: Company, Systematix Institutional Research

Exhibit 2: FY25 loan growth to normalize to 22-25% yoy




Source: Company, Systematix Institutional Research

Exhibit 4: Lowest cost of funds (amongst SFBs) backed by strong liability franchise




Source: Company, Systematix Institutional Research *on calculated basis

Exhibit 3: Highest CASA ratio amongst peer SFBs




Source: Company, Systematix Institutional Research

Exhibit 5: FY25 NIM to increase on higher CDR and impact of recent MCLR hikes




Source: Company, Systematix Institutional Research

Exhibit 6: Opex/avg assets to remain around current levels




Source: Company, Systematix Institutional Research

Exhibit 7: Stable NNPA trends led by strong focus on recoveries




Source: Company, Systematix Institutional Research

Exhibit 8: Almost NIL write-offs led by emphasis on collections/recoveries



Source: Company, Systematix Institutional Research

Exhibit 9: RoA to expand to 1.4% in FY25



Source: Company, Systematix Institutional Research

Exhibit 10: Peer Comparison (as of FY24)

| Banks | AU SFB | Ujjivan | Equitas | Capital SFB | Suryoday | Jana | ESAF | IDFC First | CUB | Federal Bank | TMB | KVB | RBL Bank | YES Bank |
|--------------------------|--------|---------|---------|-------------|----------|-------|------|------------|------|--------------|------|------|----------|----------|
| Loan growth (%) | 25.2 | 26.3 | 20.0 | 11.9 | 34.3 | 30.1 | 31.4 | 28.2 | 5.7 | 20.0 | 6.6 | 16.7 | 19.6 | 12.1 |
| Deposit growth (%) | 25.7 | 23.2 | 42.3 | 14.0 | 50.5 | 38.2 | 35.5 | 38.7 | 6.2 | 18.3 | 3.7 | 16.3 | 21.9 | 22.5 |
| LDR (%) | 83.9 | 85.4 | 85.7 | 81.2 | 103.9 | 102.4 | 92.1 | 97.0 | 81.8 | 82.9 | 80.2 | 82.7 | 81.2 | 85.5 |
| Leverage ratio (%) | 8.5 | 7.5 | 7.2 | 9.6 | 6.6 | 10.9 | 15.7 | 10.5 | 8.7 | 11.2 | 8.1 | 10.5 | 9.0 | 9.2 |
| CASA Ratio (%) | 33.4 | 26.5 | 32.0 | 38.3 | 20.1 | 19.7 | 22.7 | 47.2 | 30.6 | 29.4 | 29.6 | 30.4 | 35.2 | 30.9 |
| Asset yields (%) | 10.8 | 15.9 | 14.2 | 9.4 | 14.9 | 14.1 | 17.0 | 11.9 | 8.0 | 8.4 | 8.6 | 8.7 | 10.5 | 8.7 |
| Cost of funds (%) | 6.4 | 7.3 | 7.3 | 5.9 | 6.9 | 7.5 | 8.4 | 6.1 | 5.4 | 5.5 | 5.3 | 5.2 | 5.9 | 6.1 |
| NIM (%) | 5.3 | 9.5 | 8.0 | 4.1 | 9.0 | 7.5 | 10.7 | 6.5 | 3.2 | 3.1 | 3.8 | 4.0 | 5.1 | 2.5 |
| Cost to income ratio (%) | 63.6 | 54.3 | 64.5 | 62.5 | 61.6 | 57.4 | 58.6 | 72.2 | 47.1 | 54.5 | 47.0 | 48.3 | 66.6 | 74.4 |
| Credit costs (%) | 0.7 | 0.9 | 1.1 | 0.1 | 2.4 | 3.3 | 3.7 | 1.4 | 0.6 | 0.1 | 0.2 | 1.1 | 2.3 | 0.9 |
| RoA (%) | 1.6 | 3.5 | 2.0 | 1.3 | 1.9 | 2.3 | 1.8 | 1.1 | 1.5 | 1.3 | 1.8 | 1.6 | 0.9 | 0.3 |
| RoE (%) | 13.7 | 26.1 | 14.4 | 14.6 | 12.7 | 24.9 | 28.9 | 11.6 | 12.8 | 14.7 | 14.6 | 17.2 | 8.2 | 3.0 |
| GNPA Ratio (%) | 1.7 | 2.2 | 2.6 | 2.8 | 2.8 | 2.1 | 4.8 | 1.9 | 4.0 | 2.1 | 1.4 | 1.4 | 2.7 | 1.7 |
| NNPA Ratio (%) | 0.6 | 0.3 | 1.2 | 1.4 | 0.8 | 0.6 | 2.3 | 0.6 | 2.0 | 0.6 | 0.9 | 0.4 | 0.7 | 0.6 |
| PCR (%) | 67.6 | 87.5 | 56.1 | 50.0 | 71.2 | 73.7 | 53.7 | 68.8 | 51.5 | 72.3 | 41.6 | 71.4 | 72.7 | 66.6 |
| NNPA to Equity (%) | 3.2 | 1.4 | 6.0 | 7.1 | 3.9 | 3.6 | 16.6 | 3.6 | 10.7 | 4.3 | 4.2 | 3.0 | 4.2 | 3.2 |
| CAR - BASEL III (%) | 20.1 | 24.7 | 21.7 | 27.4 | 28.4 | 20.3 | 23.3 | 16.1 | 23.8 | 16.1 | 29.4 | 16.7 | 16.2 | 15.4 |
| Tier 1 (%) | 18.8 | 22.6 | 20.7 | 22.8 | 26.5 | 19.0 | 19.7 | 13.4 | 22.8 | 14.6 | 28.0 | 15.5 | 14.4 | 12.2 |
| Tier 2 (%) | 1.3 | 2.1 | 1.0 | 4.6 | 1.9 | 1.3 | 3.6 | 2.7 | 1.0 | 1.5 | 1.4 | 1.2 | 1.8 | 3.2 |
| Branch | 476 | 752 | 964 | 177 | 695 | 808 | 753 | 944 | 800 | 1,504 | 552 | 838 | 545 | 1,453 |

Source: Company, Systematix Institutional Research *ratios are on calculated basis

FINANCIALS

Profit & Loss Statement

| YE: Mar (Rs mn) | FY21 | FY22 | FY23 | FY24 |
|---------------------|--------------|--------------|--------------|--------------|
| Interest Earned | 5,114 | 5,782 | 6,760 | 7,943 |
| Interest Expended | 3,128 | 3,229 | 3,540 | 4,492 |
| NII | 1,986 | 2,553 | 3,220 | 3,452 |
| Other Income | 458 | 542 | 495 | 681 |
| Total Income | 2,444 | 3,095 | 3,715 | 4,132 |
| Operating Expenses | 1,730 | 1,963 | 2,228 | 2,583 |
| PPOP | 715 | 1,132 | 1,487 | 1,549 |
| Provisions | 177 | 287 | 245 | 67 |
| PBT | 537 | 845 | 1,242 | 1,482 |
| Tax | 130 | 219 | 306 | 367 |
| PAT | 408 | 626 | 936 | 1,115 |

Source: Company, Systematix Institutional Research

Balance Sheet

| YE: Mar (Rs mn) | FY21 | FY22 | FY23 | FY24 |
|--|---------------|---------------|---------------|---------------|
| Capital & Liabilities | | | | |
| Capital | 339 | 340 | 343 | 450 |
| Reserve and Surplus | 4,169 | 4,817 | 5,764 | 11,524 |
| Deposits | 52,211 | 60,464 | 65,606 | 74,777 |
| Borrowings | 6,167 | 4,984 | 7,214 | 4,723 |
| Other Liabilities and provisions | 827 | 934 | 982 | 1,479 |
| Total | 63,712 | 71,539 | 79,908 | 92,953 |
| Assets | | | | |
| Cash and Balances with RBI | 7,217 | 3,640 | 4,627 | 5,690 |
| Balances With banks and Money at call and Short Notice | 5,687 | 6,551 | 4,182 | 7,522 |
| Investments | 12,123 | 13,571 | 14,886 | 17,057 |
| Advances | 37,269 | 46,348 | 54,287 | 60,747 |
| Fixed assets | 866 | 836 | 826 | 837 |
| Other Assets | 551 | 594 | 1,101 | 1,100 |
| Total | 63,712 | 71,539 | 79,908 | 92,953 |

Source: Company, Systematix Institutional Research

Dupont (%) on Average total assets

| YE: Mar | FY21 | FY22 | FY23 | FY24 |
|---------------------|-------------|--------------|--------------|--------------|
| Interest Earned | 8.7% | 8.6% | 8.9% | 9.2% |
| Interest Expended | 5.3% | 4.8% | 4.7% | 5.2% |
| NII | 3.4% | 3.8% | 4.3% | 4.0% |
| Other Income | 0.8% | 0.8% | 0.7% | 0.8% |
| Total Income | 4.2% | 4.6% | 4.9% | 4.8% |
| Operating Expenses | 3.0% | 2.9% | 2.9% | 3.0% |
| PPOP | 1.2% | 1.7% | 2.0% | 1.8% |
| Provisions | 0.3% | 0.4% | 0.3% | 0.1% |
| PBT | 0.9% | 1.2% | 1.6% | 1.7% |
| Tax | 0.2% | 0.3% | 0.4% | 0.4% |
| PAT (RoAA) | 0.7% | 0.9% | 1.2% | 1.3% |
| RoE | 9.5% | 12.9% | 16.6% | 14.6% |

Source: Company, Systematix Institutional Research

Key Metrics (%)

| YE: Mar | FY21 | FY22 | FY23 | FY24 |
|-------------------------------|-------|-------|-------|-------|
| Yields (% of IEA) | 8.2% | 8.7% | 9.1% | 9.4% |
| Reported Cost of Deposits (%) | 5.7% | 5.0% | 4.9% | 5.6% |
| Reported NIM (%) | 3.4% | 3.8% | 4.2% | 3.9% |
| CASA ratio (%) | 40.1% | 42.2% | 41.9% | 38.3% |
| Retail deposit (%) | 97.6% | 97.4% | 97.9% | 92.9% |
| LCR (%) | 454% | 309% | 210% | 249% |
| CRAR (%) | 19.8% | 18.6% | 18.9% | 27.4% |
| Tier - 1 (%) | 14.3% | 13.2% | 13.7% | 22.8% |
| GNPA (%) | 2.1% | 2.5% | 2.8% | 2.8% |
| NNPA (%) | 1.1% | 1.4% | 1.4% | 1.4% |
| PCR (%) | 46.1% | 46.0% | 51.5% | 50.0% |
| Tax rate (%) | 24.1% | 25.9% | 24.6% | 24.7% |
| Reported credit costs (%) | 0.3% | 0.4% | 0.3% | 0.1% |
| Opex to assets (%) | 3.0% | 2.9% | 2.9% | 3.0% |
| Reported CDR (%) | 67.5% | 70.6% | 78.0% | 79.0% |
| Cost to income (%) | 70.8% | 63.4% | 60.0% | 62.5% |

Source: Company, Systematix Institutional Research

Institutional Equities Team

| | | | |
|---|--------------------------|-------------------------|----------------------------------|
| Nikhil Khandelwal | Managing Director | +91-22-6704 8001 | nikhil@systematixgroup.in |
| Equity Research | | | |
| Analysts | Industry Sectors | Desk-Phone | E-mail |
| Dhananjay Sinha Co Head of Equities & Head of Research - Strategy & Economics +91-22-6704 8095 dhananjaysinha@systematixgroup.in | | | |
| Abhishek Mathur FMCG +91-22-6704 8059 abhishekmathur@systematixgroup.in | | | |
| Ashish Poddar Consumer Durables, EMS, Building Materials, Small-Mid Caps +91-22-6704 8039 ashishpoddar@systematixgroup.in | | | |
| Himanshu Nayyar Consumer Staples & Discretionary +91-22-6704 8079 himanshunayyar@systematixgroup.in | | | |
| Manjith Nair Banking, Insurance +91-22-6704 8065 manjithnair@systematixgroup.in | | | |
| Pradeep Agrawal NBFCs & Diversified Financials +91-22-6704 8024 pradeepagrawal@systematixgroup.in | | | |
| Pratik Tholiya Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps +91-22-6704 8028 pratiktholiya@systematixgroup.in | | | |
| Sameer Pardikar IT & ITES +91-22-6704 8041 sameerpardikar@systematixgroup.in | | | |
| Santosh Yellapu Capital Goods +91-22-6704 8094 santoshyellapu@systematixgroup.in | | | |
| Shweta Dikshit Metals & Mining +91-22-6704 8042 shwetadikshit@systematixgroup.in | | | |
| Sudeep Anand Oil & Gas, Logistics, Cement, Wagons +91-22-6704 8085 sudeepanand@systematixgroup.in | | | |
| Vishal Manchanda Pharmaceuticals and Healthcare +91-22-6704 8064 vishalmanchanda@systematixgroup.in | | | |
| Chetan Mahadik Consumer Staples & Discretionary +91-22-6704 8091 chetanmahadik@systematixgroup.in | | | |
| Deeksha Bhardwaj Strategy & Economics +91-22-6704 8017 deekshabhardwaj@systematixgroup.in | | | |
| Devanshi Kamdar IT & ITES +91-22-6704 8098 devanshikamdar@systematixgroup.in | | | |
| Hinal Kothari Metals & Mining +91-22-6704 8076 hinalkothari@systematixgroup.in | | | |
| Jennisa Popat Oil & Gas, Logistics, Cement, Wagons +91-22-6704 8066 jennisapopat@systematixgroup.in | | | |
| Kalash Jain Midcaps +91-22-6704 8038 kalashjain@systematixgroup.in | | | |
| Krishna Zaveri Consumer Durables, EMS, Building Materials, Small-Mid Caps +91-22-6704 8023 krishazaveri@systematixgroup.in | | | |
| Mahek Shah Consumer Durables, EMS, Building Materials, Small-Mid Caps +91-22-6704 8040 mahekshah@systematixgroup.in | | | |
| Nirali Chheda Banking, Insurance +91-22-6704 8019 niralichheda@systematixgroup.in | | | |
| Pashmi Chheda Banking, Insurance +91-22-6704 8063 pashmichheda@systematixgroup.in | | | |
| Pravin Mule NBFCs & Diversified Financials +91-22-6704 8034 pravinmule@systematixgroup.in | | | |
| Prathmesh Kamath Oil & Gas, Logistics, Cement, Wagons +91-22-6704 8022 prathmeshkamath@systematixgroup.in | | | |
| Purvi Mundhra Macro-Strategy +91-22-6704 8078 purvimumdhra@systematixgroup.in | | | |
| Rajesh Mudaliar Consumer Staples & Discretionary +91-22-6704 8084 rajeshmudaliar@systematixgroup.in | | | |
| Ronak Dhruv NBFCs & Diversified Financials +91-22-6704 8045 ronakdhruv@systematixgroup.in | | | |
| Rushank Mody Pharmaceuticals and Healthcare +91-22-6704 8046 rushankmody@systematixgroup.in | | | |
| Swati Saboo Midcaps +91-22-6704 8043 swatisaboo@systematixgroup.in | | | |
| Yogeeta Rathod Midcaps +91-22-6704 8081 yogeetarathod@systematixgroup.in | | | |
| Equity Sales & Trading | | | |
| Name | | Desk-Phone | E-mail |
| Vipul Sanghvi Co Head of Equities & Head of Sales +91-22-6704 8062 vipulsanghvi@systematixgroup.in | | | |
| Jignesh Desai Sales +91-22-6704 8068 jigneshdesai@systematixgroup.in | | | |
| Sidharth Agrawal Sales +91-22-6704 8090 sidharthagrawal@systematixgroup.in | | | |
| Shreya Chaudhary Sales +91-22-6704 8033 shreyachaudhary@systematixgroup.in | | | |
| Rahul Khandelwal Sales +91-22-6704 8003 rahul@systematixgroup.in | | | |
| Chintan Shah Sales +91-22-6704 8061 chintanshah@systematixgroup.in | | | |
| Pawan Sharma Director and Head - Sales Trading +91-22-6704 8067 pawansharma@systematixgroup.in | | | |
| Mukesh Chaturvedi Vice President and Co Head - Sales Trading +91-22-6704 8074 mukeshchaturvedi@systematixgroup.in | | | |
| Vinod Bhuwad Sales Trading +91-22-6704 8051 vinodbhuwad@systematixgroup.in | | | |
| Rashmi Solanki Sales Trading +91-22-6704 8097 rashmisolanki@systematixgroup.in | | | |
| Karan Damani Sales Trading +91-22-6704 8053 karandamani@systematixgroup.in | | | |
| Vipul Chheda Dealer +91-22-6704 8087 vipulchheda@systematixgroup.in | | | |
| Paras Shah Dealer +91-22-6704 8047 parasshah@systematixgroup.in | | | |
| Rahul Singh Dealer +91-22-6704 8054 rahulsingh@systematixgroup.in | | | |
| Niraj Singh Dealer +91-22-6704 8096 nirajsingh@systematixgroup.in | | | |
| Corporate Access | | | |
| Mrunal Pawar Vice President & Head Corporate Access +91-22-6704 8088 mrunalpawar@systematixgroup.in | | | |
| Darsha Hiwrale Associate Corporate Access +91-22-6704 8083 darshahiwrale@systematixgroup.in | | | |
| Production | | | |
| Madhu Narayanan Editor +91-22-6704 8071 madhunarayanan@systematixgroup.in | | | |
| Mrunali Pagdhare Production +91-22-6704 8057 mrunalip@systematixgroup.in | | | |
| Vijayendra Achrekar Production +91-22-6704 8089 vijayendraachrekar@systematixgroup.in | | | |
| Operations | | | |
| Sachin Malusare Vice President +91-22-6704 8055 sachinmalusare@systematixgroup.in | | | |
| Jignesh Mistry Manager +91-22-6704 8049 jigneshmistry@systematixgroup.in | | | |
| Hiren Patel Assistant Manager +91-22-6704 8056 hirenpatel@systematixgroup.in | | | |

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Manjith Nair, Pashmi Chheda, Nirali Chheda**, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

| Disclosure of Interest Statement | Update |
|--|--------|
| Analyst holding in the stock | No |
| Served as an officer, director or employee | No |

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

| Sr. No. | Particulars | Yes / No. |
|---------|---|-----------|
| 1 | Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL. | No |
| 2 | Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report. | No |
| 3 | Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report. | No |
| 4 | Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months. | No |
| 5 | Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months. | No |

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSL through this presentation.

SSSL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSL and certification from NISM to the analyst in no way guarantee performance of SSSL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917